Cannabis for Chronic Headaches in Adolescents: the CAN-CHA Trial

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 11, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Chronic Migraine
Interventions
DRUG

MPL-001

"CBD50 plus is a medical cannabis oil with flavouring agent produced under Good Manufacturing Practice by MediPharm Labs and purchased for this study. Each ml of oil contains 2 mg/ml of delta-9-THC and 50 mg/ml of CBD.~Participants will receive escalating doses from 0.2-0.4 mg/kg/day of CBD to 0.8-1 mg/kg of CBD per day for four months, with dose increases monthly in 0.2mg/kg increments. Participants will following a weekly weaning protocol."

Trial Locations (3)

V6T1Z4

NOT_YET_RECRUITING

University of British Columbia, Vancouver

B3K 6R8

NOT_YET_RECRUITING

Dalhousie University-, Halifax

Unknown

RECRUITING

North Toronto Neurology, Toronto

All Listed Sponsors
collaborator

SickKids Foundation

OTHER

lead

University of Manitoba

OTHER